Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

L19IL2 o L19TNF o L19IL2/TNF in Pazienti con Carcinoma Basocellulare (BCC)

5 novembre 2026 aggiornato da: Philogen S.p.A.

Uno studio controllato randomizzato di fase 2 sull'efficacia delle iniezioni intralesionali di L19IL2 o L19TNF o L19IL2/L19TNF per il trattamento del carcinoma basocellulare localmente avanzato (LaBCC)

Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms of the study and will receive intralesional injections of: (i) Monotherapy 13 Mio IU (~2.17 mg) L19IL2; or (ii) Monotherapy 0.4 mg L19TNF; or (iii) Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF, once weekly for 4 consecutive weeks. Patients will be followed for a maximum of 156 weeks after beginning of treatment.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Tumor Assessment (TA) visits will be performed at Week 8 (Day 50 from the beginning of treatment), Week 12 (Day 78), Week 16 (Day 106) and then every 8 weeks for the first year of Follow-up (FU). During second and third years of FU, TA visits will be performed every 12 Weeks. In case a response (CR, PR) or stable disease (SD) is observed, a confirmatory assessment of the tumor response will be performed 4 weeks after the TA visit, when the objective response was first recorded.

Tumor response shall be evaluated according to composite criteria, i.e. BCC-RECIST-like. Measurement of tumor lesions and documentation (photographic documentation with use of a caliper for cutaneous lesions; ultrasound for subcutaneous lesions; imaging techniques as MRI) will be performed at every TA visit.

Confirmation of response or stable disease will be assessed by histopathological analysis of specimens from the treated skin area by multiple punch biopsies. Confirmation of tumor responses will be centrally reviewed by an independent committee (Independent Central Review, ICR).

After the TA visit confirmatory of partial response or stable disease, surgery with a curative intention can be performed if considered appropriate in the judgement of the investigator and if agreed upon by the patient; in these cases, pathological response in the exeresis specimen(s) will be evaluated as described above.

Patients will be followed for overall survival (OS) after a relapse or progression, and any further treatment given will be recorded for three years. Phone contact or any other documented contact with the patient will be recorded every 6 months for OS assessment from treatment start until the death of the patient, withdrawal of consent or until study completion (LPLV).

L19IL2 or L19TNF or L19IL2/L19TNF will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients will receive intratumoral administrations of immunocytokines into injectable cutaneous, and subcutaneous tumors once weekly for up to 4 weeks.

On the day of each treatment visit, all tumors to be injected should be measured and recorded (using caliper/ruler for cutaneous lesions and/or ultrasound for subcutaneous lesions). The recommended volume to be injected into the tumor(s) is dependent on the size of the lesion(s). The maximum dose to be administered in a single treatment visit is:

i) 13 MioIU L19IL2, or ii) 0.4 mg L19TNF or iii) 13 MioIU L19IL2 + 0.4 mg L19TNF It is recommended that each lesion should receive the maximum amount possible to inject due to tumor properties at each visit.

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Augsburg, Germania, 86179
        • Reclutamento
        • Universitaetsklinikum Augsburg
        • Investigatore principale:
          • Julia Welzel, Prof.
      • Berlin, Germania, 10117
        • Reclutamento
        • Charite Universitaetsmedizin Berlin KöR
        • Investigatore principale:
          • Thomas Eigentler, Prof.
      • Essen, Germania, 45147
        • Reclutamento
        • Universitaetsklinikum Essen AöR
        • Investigatore principale:
          • Dirk Schadendorf, Prof.
      • Halle, Germania, 06120
        • Reclutamento
        • Universitaetsklinikum Halle (Saale) AöR
        • Investigatore principale:
          • Johannes Wohlrab
      • Kiel, Germania, 24105
        • Reclutamento
        • Universitaetsklinikum Schleswig-Holstein AöR
        • Investigatore principale:
          • Katharina Kahler
      • Tübingen, Germania, 72076
        • Reclutamento
        • Universitaetsklinikum Tuebingen AöR
        • Investigatore principale:
          • Lukas Flatz, Prof.
      • Athens, Grecia, 16121
        • Non ancora reclutamento
        • Andreas Syngros Hospital Of Venereal And Dermatological Diseases
        • Investigatore principale:
          • Alexandros Stratigos, Prof.
      • Naples, Italia, 80131
        • Reclutamento
        • IRCCS Istituto Nazionale Tumori Fondazione Pascale
        • Investigatore principale:
          • Paolo Ascierto, Prof.
      • Roma, Italia, 00168
        • Reclutamento
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Investigatore principale:
          • Ketty Peris, Prof.
      • Rozzano, Italia, 20089
        • Reclutamento
        • Humanitas Mirasole S.p.A.
        • Investigatore principale:
          • Paolo Bossi, Prof.
      • Siena, Italia, 53100
        • Reclutamento
        • Azienda Ospedaliero-Universitaria Senese
        • Investigatore principale:
          • Annamaria Di Giacomo, Prof.
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Hospital Clinic De Barcelona
        • Investigatore principale:
          • Agustin Toll Abello, Prof.
    • Florida
      • Tampa, Florida, Stati Uniti, 33612
        • Reclutamento
        • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
        • Investigatore principale:
          • Jonathan S Zager, MD
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Winship Cancer Institute, Emory University
        • Investigatore principale:
          • Michael C. Lowe, MD
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Investigatore principale:
          • Melodi J Whitley, MD
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • Non ancora reclutamento
        • University Hospitals Cleveland Medical Center
        • Investigatore principale:
          • Luke D. Rothermel, MD
      • Columbus, Ohio, Stati Uniti, 43210
        • Non ancora reclutamento
        • The Ohio State University Wexner Medical Center Clinical Laboratories
        • Investigatore principale:
          • Carlo Contreras, MD
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas MD Anderson Cancer Center
        • Investigatore principale:
          • Michael R Migden, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients with high risk, locally advanced histologically confirmed (non-metastatic, node negative, single or multifocal), BCC and amenable to intratumoral injection, not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board.

  • Patients with at least one injectable and measurable cutaneous or subcutaneous lesion.

  • Patients must not have received prior HHIs and checkpoint inhibitors systemic treatment.

  • Patients may have received prior surgery and/or radiation therapy.

  • Radiotherapy must have been previously administered for their locally advanced BCC, unless radiotherapy is contraindicated or inappropriate (e.g., hypersensitivity to radiation due to genetic syndrome such as Gorlin syndrome, limitations because of location of tumor, or cumulative prior radiotherapy dose). For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.

  • Patients must have a histologically confirmed disease that is considered to be inoperable or medical contraindication to surgery or radiotherapy, in the opinion of a Mohs dermatologic surgeon, head and neck surgeon, plastic surgeon or surgical/medical oncologist. Acceptable medical contraindications to surgery include:

    • BCC that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely;
    • Anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation);
    • Medical conditions predisposing to poor surgical outcome (e.g., diabetes with history of poor wound healing);
    • Other conditions considered to be medically contraindicating must be discussed with the Medical Monitor before enrolling the patient.
  • Prior radiotherapy to the target lesions must be completed at least 4 weeks prior to first study drug administration, with all acute RT-related toxicities resolved to ≤ Grade 1.

  • Male or female patients, who are capable of giving consent, age ≥ 18 years.

  • ECOG Performance Status/WHO Performance Status ≤ 1.

  • Hemoglobin > 10.0 g/dL.

  • Platelets > 100 x 109/L.

  • ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).

  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.

  • Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner.

  • Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.

  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  • Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated squamous-cell carcinoma of the skin (surgically removed 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study.
  • Current topical or systemic chemotherapy, targeted therapy immunotherapy.
  • Patients with node positive BCC who are candidates for checkpoint inhibitor therapy.
  • Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2.
  • Presence of active severe bacterial or viral infections or other severe concurrent disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
  • Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
  • Known arterial aneurysms.
  • INR > 3.
  • Uncontrolled hypertension.
  • Known uncontrolled coagulopathy or bleeding disorder.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Moderate to severe respiratory failure.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
  • Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  • Pregnancy or breast-feeding.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe diabetic retinopathy.
  • Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
  • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: L19IL2

Patient will receive intralesional injections of monotherapy 13 Mio IU (~2.17 mg) L19IL2. Frequency and duration are identical for all arms.

Intratumoral injections

Sperimentale: L19IL2/L19TNF

Patient will receive intralesional injections of Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF. Frequency and duration are identical for all arms.

Intratumoral injections

Sperimentale: L19TNF

Patient will receive intralesional injections of monotherapy 0.4 mg L19TNF. Frequency and duration are identical for all arms.

Intratumoral injections

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Best Overall Response Rate
Lasso di tempo: from enrollment to week 16

Confirmed Best Overall Response Rate per BCC-RECIST-like criteria according to ICR by Week 16.

from enrollment to week 16

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 settembre 2026

Completamento primario (Stimato)

1 febbraio 2031

Completamento dello studio (Stimato)

1 febbraio 2031

Date di iscrizione allo studio

Primo inviato

7 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

7 novembre 2025

Primo Inserito (Effettivo)

12 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • PH-L19IL2TNFCOMB-04/24
  • 2025-523229-16-00 (Ctis)
  • 2025 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .